Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.

The Prostate - 15 Jun 2003

Chang Bao-Li, Zheng S Lilly, Isaacs Sarah D, Turner Aubrey R, Bleecker Eugene R, Walsh Patrick C, Meyers Deborah A, Isaacs William B, Xu Jianfeng

Abstract excerpt

BACKGROUND: The 5 alpha-reductase type II (SRD5A2) catalyzes the conversion of testosterone into the more potent androgen, dihydrotestosterone (DHT), and is thus believed to be the key enzyme for the control of intracellular DHT level in the prostate. Several single nucleotide polymorphisms (SNPs) in the SRD5A2 gene have been found to alter enzymatic activities and were associated with prostate cancer risk or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Family Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Linkage

Share to Genetic Predisposition to Disease

Share to Oxidoreductases

Share to Polymorphism, Genetic

Share to Prostatic Neoplasms

Share to Risk Factors

Source

Identifiers

PMID: 12746845
DOI: 10.1002/pros.10225

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.PMID 12746845Read ↗

Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review.Semantic proximity Read ↗

No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.Semantic proximity Read ↗

Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway.Semantic proximity Read ↗

Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.Semantic proximity Read ↗

Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.Semantic proximity Read ↗

SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.Semantic proximity Read ↗

Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer.Semantic proximity Read ↗

Pharmacogenetics of human androgens and prostatic diseases.Semantic proximity Read ↗

SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis.Semantic proximity Read ↗

Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.Semantic proximity Read ↗

Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk.Semantic proximity Read ↗

Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.